59 Citations (Scopus)

Abstract

Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.

Original languageEnglish (US)
Pages (from-to)675-677
Number of pages3
JournalNature Medicine
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Phosphatidylinositol 3-Kinases
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Cell Survival
Phosphotransferases
Cells
Mutation

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

HER3 and mutant EGFR meet MET. / Arteaga, Carlos L.

In: Nature Medicine, Vol. 13, No. 6, 01.06.2007, p. 675-677.

Research output: Contribution to journalShort survey

Arteaga, Carlos L. / HER3 and mutant EGFR meet MET. In: Nature Medicine. 2007 ; Vol. 13, No. 6. pp. 675-677.
@article{12cc7462fab7490aaa49587f610fb048,
title = "HER3 and mutant EGFR meet MET",
abstract = "Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.",
author = "Arteaga, {Carlos L.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1038/nm0607-675",
language = "English (US)",
volume = "13",
pages = "675--677",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - HER3 and mutant EGFR meet MET

AU - Arteaga, Carlos L.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.

AB - Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.

UR - http://www.scopus.com/inward/record.url?scp=34249984736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249984736&partnerID=8YFLogxK

U2 - 10.1038/nm0607-675

DO - 10.1038/nm0607-675

M3 - Short survey

C2 - 17554333

AN - SCOPUS:34249984736

VL - 13

SP - 675

EP - 677

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 6

ER -